Canadian corporate legislation provides shareholders with the right to dissent to certain corporate actions, including a proposed amalgamation, an amendment to the articles of the corporation, continuation into another jurisdiction, sale of all or substantially all of the corporation’s assets or the implementation of an arrangement.

While dissent rights are not often utilized by shareholders of Canadian corporations, similar appraisal rights are commonly utilized in merger and acquisition transactions in the United States and provide shareholders with the opportunity to test pricing on significant transactions. This opportunity has become increasingly important in light of increased market volatility and the uptick in management-led buyouts. By providing shareholders with the ability to challenge the consideration they are receiving, dissent rights not only encourage comprehensive market tests, but may also increase competitive tension in transactions.

The Gold Flora decision

To highlight the potential impact of dissent rights, a recent case from the British Columbia Supreme Court, Michalowski (Trustee) v Gold Flora, 2025 , provided dissenting shareholders with a significant increase over the trading price of the shares at the time the transaction was approved by shareholders. The decision also provides insight into how a court will determine the payout value of the shares held by dissenting shareholders under the dissent proceedings provisions of the Business Corporations Act (British Columbia) (the BCBCA).

The petitioners in Gold Flora were minority shareholders of TPCO Holding Corp., a publicly traded and BC-incorporated cannabis company. The petitioners dissented in respect of the 2023 merger of TPCO with Gold Flora LLC by way of plan of arrangement to form the Gold Flora Corporation (the Respondent), and petitioned the court seeking a determination of the payout value of their shares under the BCBCA.

The petitioners argued that the payout value should be equal to the share price used by the parties to negotiate the share exchange ratio pursuant to the terms of the merger (~US$0.98, the merger price), whereas the Respondent argued that the payout value should be equal to TPCO’s trading price on the valuation date (US$0.17, the trading price). Ultimately, the court found that the merger price was a more accurate measurement of the fair value of TPCO’s shares than the trading price.

This case demonstrates that determining the payout value of shares held by dissenting shareholders involves a broad analysis of all relevant information and is not determined by a company’s trading price alone. In particular, where a target’s share trading is characterized by low volume and limited liquidity, the trading price is much less likely to reflect fair value.

The potential benefits and risks of exercising dissent rights

The ability to dissent under the BCBCA applies to both voting and non-voting shareholders alike. Specifically, exercising dissent rights allows dissenting shareholders to oppose a corporate action and crystalize the value of their shares in anticipation of an event that the shareholder believes undervalues or could devalue those shares. Often for public M&A transactions, the definitive agreement contains a condition in favour of the purchaser that not more than a set threshold (i.e. 5%) of shareholders will dissent.

In many circumstances, the dissenting shareholders and the company will agree to an acceptable payout value and settle dissent proceedings. As a result, dissent proceedings can allow a company to complete a corporate action while preserving the rights of those shareholders that disagree to receive fair value.

If the dissenting shareholders and the company cannot agree on a payout value for the dissenting shareholders’ shares, both the company and the shareholders are required to spend additional time and capital in seeking a court determination of the fair value of the shares.

In Gold Flora, this determination was in favour of the dissenting shareholders, who were awarded nearly 6 times more for their shares under the dissent proceedings than if they had sold them on the public market. However, no challenge is without risk, and the court may also find that the appropriate payout value is below the offered price, resulting in unnecessary time and expense for the dissenting shareholders.

Strategies to reduce risk

When a company is considering a transaction, such as a share/asset sale, merger, or plan of arrangement, it is important to understand the impact of the transaction on the company as a whole. To minimize risk when completing a corporate transaction, companies can take proactive steps to market test a corporation’s value through a robust sales process, include fiduciary outs for competing offers in their transaction agreements, seek fairness opinions and valuations from trusted experts, and prioritize alignment with key stakeholders once the transaction has been announced.

  1. Robust sales process

    When a company is considering a significant transaction or corporate action, it should be thoroughly canvassing and assessing the available alternatives with the help of its legal and financial advisors. A robust sales process can minimize the number of shareholders that would otherwise dissent to the transaction, by providing assurance that the transaction is in the best interests of the company as a whole. The importance of this step is enhanced in unsolicited offers and in go-private transactions where management forms part of the buying group.
  2. Fiduciary outs for competing offers

    Directors have a fiduciary duty to act in the best interests of their corporation. Accordingly, companies should ensure the binding agreements they enter into for a significant transaction preserve the ability for the company’s board of directors to act in the company’s best interest by abandoning the transaction in favour of a superior proposal. These fiduciary outs can help prevent dissent amongst shareholders by providing assurance that the board is continuously assessing competing offers throughout the transaction process.
  3. Fairness opinion/valuation

    A company can further assure its shareholders of a potential transaction’s value by seeking fairness opinions and valuations from trusted independent experts. These opinions and the underlying analysis serve to instill confidence in shareholders that a potential transaction is in their best interest, thus minimizing the risk of shareholder dissent once the transaction is complete.
  4. Alignment with key stakeholders

    Once a company has decided a transaction or significant corporate event is in the best interests of the company, the transacting company can reduce the risk of shareholder opposition and dissent by prioritizing alignment with its key stakeholders. Company management should consider proactively approaching its key stakeholders to explain why the deal was in the company’s best interests and why stakeholders should support it. By assuaging stakeholder concerns as soon as possible, the company can minimize the risk of those concerns prompting shareholders to dissent to the deal.

Contact